The Board voted to Support HB20-1198, while Strongly Supporting the provision that prohibits changes in the formulary mid-year. The Board encourages legislators to include language that specifies the formularies can add newly approved drugs by the FDA and allowing for removal of drugs from the formulary at the direction of the FDA.